


Multi-state Models and the Survival package



Terry Therneau




Sept 2019





Background

- ▶ I am a medical statistician in a tertiary care center
- ▶ Most of the questions are time until ...
 - ▶ waiting time on the liver transplant list
 - ▶ failure of a hip replacement (if ever)
 - ▶ clinical trial: chemotherapy to relapse
 - ▶ CN → MCI → Dementia
 - none vs. mild vs. moderate/severe neurodegeneration
 - none/mild vs. moderate amyloid deposition
- ▶ Naturally fell into survival analysis.









Outline

- ▶ Three research studies
 - ▶ MGUS
 - ▶ Leukemia
 - ▶ Fatty liver disease
- ▶ R code along the way

Outline

- ▶ Three research studies
 - ▶ MGUS
 - ▶ Leukemia
 - ▶ Fatty liver disease
- ▶ R code along the way
- ▶ Main points
 - ▶ Multi-state approach is very useful
 - ▶ It ain't that hard

The survival package

- ▶ Does what I need it to do
- ▶ Building block for others (666 dependencies on 9/10)

The survival package



- ▶ Does what I need it to do
- ▶ Building block for others (666 dependencies on 9/10)
- ▶ survival3 went to CRAN on Wed
- ▶ Major change/enhancement: multistate

MGUS

- ▶ Observation of Dr Robert Kyle
 - ▶ semi-abnormal lab test in normal people (PE)
 - ▶ reminiscent of multiple myeloma results
 - ▶ are these subjects at risk of MM?
 - ▶ note every one he sees, and follow them
- ▶ mgus2 data set in R
 - ▶ 1384 sequential subjects
 - ▶ 5–35 years of follow-up
 - ▶ Death, PCM, age, sex, + 3 labs

Data



	id	age	sex	creat	futime	death	ptime	pstat
79	79	96	M	1.8	33	1	33	0
80	80	80	M	1.1	68	1	68	0
81	81	91	F	1.0	21	1	14	1
82	82	71	M	1.1	65	1	65	0
83	83	77	F	0.8	233	1	228	1



	id	tstart	tstop	event	age	sex	hgb	enum
80	79	0	33	Death	96	M	9.6	1
81	80	0	68	Death	80	M	14.1	1
82	81	0	14	PCM	91	F	5.9	1
83	81	14	21	Death	91	F	5.9	2
84	82	0	65	Death	71	M	15.6	1
85	83	0	228	PCM	77	F	12.2	1
86	83	228	233	Death	77	F	12.2	2
87	84	0	78	Death	89	M	14.3	1

```
# Kaplan-Meier
kmfit <- survfit(Surv(futime, death) ~ sex, data=mgus2)

# Competing risks
crdata <- subset(mdata, enum==1)
crfit <- survfit(Surv(tstop, event) ~ sex, data=crdata)
```




```
# Kaplan-Meier and Cox model
```

```
kmfit <- survfit(Surv(futime, death) ~ sex, data=mgus2)
```

```
cfit <- coxph(Surv(futime, death) ~ sex + age, data=mgus2)
```

```
# Competing risks and Cox model
```

```
crfit <- survfit(Surv(tstop, event) ~ sex, data=crdata)
```

```
cfit2 <- coxph(Surv(tstop, event) ~ sex + age10, data=crdata, id=id)
```

Call:

```
coxph(formula = Surv(tstop, event) ~ sex + age10, data = crdata,  
      id = id)
```

1:2		coef	exp(coef)	se(coef)	robust se	z	p
	sexM	-0.025	0.975	0.188	0.189	-0.1	0.89
	age10	0.130	1.139	0.083	0.067	1.9	0.05

1:3		coef	exp(coef)	se(coef)	robust se	z	p
	sexM	0.393	1.482	0.070	0.066	5.9	3e-09
	age10	0.648	1.912	0.036	0.037	17.6	<2e-16



States: 1= (s0), 2= PCM, 3= Death

Likelihood ratio test=390 on 4 df, p=<2e-16

n= 1384, number of events= 975


- ▶ Sex has absolutely no effect on the instantaneous risk of PCM
- ▶ Females *do* have an increased lifetime risk of PCM, however.
 - ▶ The malignancy rate is 1% per year
 - ▶ Females live longer

```
dummy <- expand.grid(sex= c("M", "F"), age10 = c(6, 8))  
sfit <- survfit(cfit2, newdata=dummy)    # dimension (4, 3)  
plot(sfit[1:2,])  
plot(sfit[3:4,])
```




Acute Myeloid Leukemia

- ▶ Clinical trial of two induction therapies
- ▶ Surprising interaction in the data
- ▶ “Can we sort this out?”



Acute Myeloid Leukemia



	id	trt	tstart	tstop	event
1	1	B	0	44	CR
2	1	B	44	113	relapse
3	1	B	113	235	death
4	2	A	0	200	SCT
5	2	A	200	286	death
6	3	A	0	38	CR
7	3	A	38	1983	none

Data

- ▶ `event` is a multi-level factor variable.
 - ▶ The first level must correspond to “no event at this time”
 - ▶ Otherwise unrestricted.
- ▶ An `id` variable identifies multiple rows per subject.
- ▶ Consistent
 - ▶ If at risk, you should be some state: (0,50,CR) (90,210,SCT)
 - ▶ But only one place at a time: (0,50,CR) (30,210,SCT)

Data check

```
check <- survcheck(Surv(tstart, tstop, event) ~ 1,  
                   data=mdata, id=id)
```

```
check$transitions
```


to


from	CR	SCT	relapse	death	(censored)
(s0)	443	106	13	55	29
CR	0	159	168	17	110
SCT	11	0	45	149	158
relapse	0	99	0	99	28
death	0	0	0	0	0

```
#
```




```
check$flag
```




overlap	gap	jump	teleport
0	0	0	0








	id	trt	tstart	tstop	event	e2
1	1	B	0	44	CR	none
2	1	B	44	113	relapse	Fail
3	1	B	113	235	death	none
4	2	A	0	200	SCT	SCT
5	2	A	200	286	death	Fail
6	3	A	0	38	CR	none
7	3	A	38	1983	none	none







Possible questions

- ▶ Does the time from CR to progression/death differ?
- ▶ Does the rate of SCT after CR differ?
- ▶ How do all of these interact with sex?

Possible questions

- ▶ Does the time from CR to progression/death differ?
- ▶ Does the rate of SCT after CR differ?
- ▶ How do all of these interact with sex?
- ▶ Why would you settle for a single (boring) KM?

AJ estimator

- ▶ The survfit routine calculates the Aalen-Johansen estimate of $p(t)$
 $p_j(t) = \text{Pr}(\text{in state } j \text{ at time } t)$
- ▶ $\sum_j p_j(t) = 1$
- ▶ IJ variance
- ▶ Kaplan-Meier = special case of AJ
- ▶ Cumulative incidence = special case of the AJ

Fatty liver disease (NAFLD)


- ▶ Definition

- ▶ presence of $> 5\%$ fat in the liver (steatosis)
- ▶ absence of other indications (alcohol or certain medications)
- ▶ no other liver disease


- ▶ Why would you care?

- ▶ responsible for 1/3 of liver transplants
- ▶ prevalence is growing with obesity

“Nonalcoholic fatty liver disease, metabolic syndrome, and the fight that will define clinical practice for a generation of hepatologists.” Tapper and Loomba, Hepatology 2018.



- ▶ NAFLD as a covariate
- ▶ Outcome of 0–3 “metabolic syndrome” comorbidities
 - ▶ diabetes
 - ▶ dyslipidemia
 - ▶ hypertension




Data


- ▶ 3514 NAFLD cases
- ▶ 14004 age/sex matched controls

Data

- ▶ 3514 NAFLD cases
- ▶ 14004 age/sex matched controls
- ▶ Use age scale
- ▶ “Duration of NAFLD” not possible



Multistate



```
check <- survcheck(Surv(age1, age2, event) ~ 1, data=data1,
  istate=cstate, id = id)
```

```
check$transitions
```

```
      to
from    1mc    2mc    3mc death (censored)
0mc    1829     70     4    263          5705
1mc         0  1843    28    243          4567
2mc         0     0  1048    417          3687
3mc         0     0     0    441          2220
death    0     0     0     0           0
```

Analysis

- ▶ Hazard ratios
- ▶ Absolute risk
 - ▶ current state $p(t)$
 - ▶ $E(\text{time in state})$
 - ▶ $E(\text{number of visits to each state})$
lifetime risk
 - ▶ $E(\text{time in state, per visit})$

Hazard model


- ▶ Default
 - ▶ separate baseline for each transition
 - ▶ separate coefficients for each transition
- ▶ 0mc:3mc has 4 cases, 1:3 only has 28
- ▶ Collapse 0:1, 0:2, 0:3 = “worsening”
- ▶ x:death as a single baseline + covariates?
- ▶ Many choices possible

Cox fits

```
cform <- list(Surv(age1, age2, event) ~ nafld + bmi,
              "0mc":c("1mc", "2mc", "3mc") ~ nafld +bmi/ common,
              "1mc":c("2mc", "3mc") ~ nafld +bmi/ common)

coxmx <- coxph(cform, istate=cstate, id= id,
              data1, subset= (male==1))
coxf <- coxph(cform, istate=cstate, id = id,
              data1, subset= (male==0))





coxmx$emap
      1:2 1:3 2:3 1:4 2:4 3:4 1:5 2:5 3:5 4:5
(Baseline)  1  2  3  4  5  6  7  8  9 10
nafld      1  1  3  1  3  5  7  9 11 13
bmi        2  2  4  2  4  6  8 10 12 14
j <- unique(coxmx$emap[2,])
temp <- rbind(male=coef(coxmx)[j], female= coef(coxf)[j])
colnames(temp) <- c("0:1", "1:2", "2:3", paste(0:3, 'death', sep=':'))
round(exp(temp),2)
      0:1  1:2  2:3 0:death 1:death 2:death 3:death
male   1.55 1.45 1.47    2.22    1.38    2.14    1.04
female 1.43 1.51 1.46    2.28    1.90    1.57    0.85
```



State at enrollment

	cstate				
naflld0	0mc	1mc	2mc	3mc	
0	51	27	16	7	
1	22	31	28	19	

Current status as a function of age



Expected future for a 50 year old with no comorbidities

```
s50a <- survfit(Surv(age1, age2, event) ~ naflld0, data=data1,  
                istate=cstate,  
                id=id, start.time=50)
```


```
s50b <- survfit(Surv(age1, age2, event) ~ naflld0, data=data1,  
                istate=cstate,  
                id=id, start.time=50,  
                p0=c(1,0,0,0,0))
```

```
print(s50b, rmean=100, digits=2)
```

```
Call: survfit(formula = Surv(age1, age2, event) ~ naflld0, data = data1,  
              id = id, istate = cstate, start.time = 50, p0 = c(1, 0, 0,  
              0, 0))
```

	n	nevent	rmean*
naflld0=0, 0mc	13309	0	15.2
naflld0=1, 0mc	3283	0	7.8
naflld0=0, 1mc	13309	980	8.9
naflld0=1, 1mc	3283	129	8.2
naflld0=0, 2mc	13309	1143	7.7
naflld0=1, 2mc	3283	327	8.2
naflld0=0, 3mc	13309	575	2.7

Time in state



Summary

- ▶ Multi-state problems are common
- ▶ Rich analysis possibilities
- ▶ Tools are getting better
- ▶ Just don't get carried away with the wrong things ...

Software goals

- ▶ Multi-state fits are as easy as `coxph`
- ▶ Curves of $P(\text{state} | t)$ are as easy as `survfit`
- ▶ Secondary summaries (time in state, $E(\text{visits to state}), \dots$)
- ▶ Better data tools
 - ▶ Rules for data
 - ▶ Cannot be in two places at once
 - ▶ If at risk, must be someplace
 - ▶ Gaps and teleports are viewed with suspicion
 - ▶ Don't make the user break the rules
 - ▶ Immortal time bias is everywhere.
- ▶ These are the tools that I use.

Software goals

- ▶ Multi-state fits are as easy as `coxph`
- ▶ Curves of $P(\text{state} | t)$ are as easy as `survfit`
- ▶ Secondary summaries (time in state, $E(\text{visits to state}), \dots$)
- ▶ Better data tools
 - ▶ Rules for data
 - ▶ Cannot be in two places at once
 - ▶ If at risk, must be someplace
 - ▶ Gaps and teleports are viewed with suspicion
 - ▶ Don't make the user break the rules
 - ▶ Immortal time bias is everywhere.
- ▶ These are the tools that I use.
- ▶ Don't bugger it up